Ablacon
AI-guided atrial fibrillation therapies company
All edits
June 22, 2021
Ablacon, Inc., developer of an advanced mapping system to guide the treatment of atrial fibrillation (AF), announced today that is has promoted Martin Grasse to the position of Chief Executive Officer.
Prior to Ablacon, Grasse led business development at EPIX Therapeutics, which was acquired by Medtronic.
Before EPIX, he worked in a variety of roles focused on electrophysiology and interventional cardiology technologies at Cibiem, Bridgepoint Medical (acquired by Boston Scientific), and St. Jude Medical.
The company also announces the 70th subject enrolled in the multicenter, randomized FLOW-AF clinical study on the use of Ablacon's product, AblaMap, in a persistent AF patient population.
June 22, 2021
June 22, 2021
Ablacon, Inc., developer of an advanced mapping system to guide the treatment of atrial fibrillation (AF), announced today that is has promoted Martin Grasse to the position of Chief Executive Officer.
Prior to Ablacon, Grasse led business development at EPIX Therapeutics, which was acquired by Medtronic.
Before EPIX, he worked in a variety of roles focused on electrophysiology and interventional cardiology technologies at Cibiem, Bridgepoint Medical (acquired by Boston Scientific), and St. Jude Medical.
The company also announces the 70th subject enrolled in the multicenter, randomized FLOW-AF clinical study on the use of Ablacon's product, AblaMap, in a persistent AF patient population.
Find more companies like Ablacon
